

Special Issue

Current Use of Hematopoietic Cell Transplantation in Hematologic Malignancies

Message from the Guest Editors

Allogeneic hematopoietic cell transplantation (allo-HCT) is a vital treatment for various hematologic malignancies. This Special Issue aims to provide a comprehensive overview of the current landscape of allo-HCT, focusing on key topics such as patient selection, conditioning regimens and the integration of immunotherapies and targeted treatments that are reshaping care practices. Emphasis will be placed on the importance of minimal residual disease (MRD) as a critical marker for predicting transplant outcomes. Advances in MRD detection techniques allow for more precise monitoring, enabling clinicians to identify patients who may benefit from pre-emptive treatments to reduce relapse rates. We will also evaluate different prophylaxis regimens for preventing disease and managing graft-versus-host disease.

Guest Editors

Dr. Marina Díaz-Beyá

Hematology Department, Hospital Clinic Barcelona, Barcelona, Spain

Dr. Maria Queralt Salas

Hematopoietic Cell Transplant Unit, Hospital Clinic de Barcelona, Barcelona, Spain

Deadline for manuscript submissions

closed (31 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/219937

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)